Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the following upcoming investor conferences and events in September:
- Alto Investor Day Focused on ALTO-100 in Major Depressive Disorder, September 9th 2024:
- Ahead of topline data expected in October 2024 for the Phase 2b study, the Company plans to provide information regarding the baseline characteristics of study participants, mechanistic and clinical rationale for ALTO-100, and the predictive cognitive test being used to select patients.
- To register for Alto’s investor day, being held on Monday, September 9, 2024, at 9:00 am ET, click here. More details are available on the Company’s investor day website.
- Baird Global Healthcare Conference, September 10-11th 2024:
- Format: Presentation and one-on-one investor meetings
- Presentation Date/Time: Wednesday, September 11, 2024, at 11:25 am ET
- Location: InterContinental New York Barclay
- Cantor Global Healthcare Conference, September 17-19th 2024:
- Format: Presentation and one-on-one investor meetings
- Presentation Date/Time: Tuesday, September 17, 2024, at 9:10 am ET
- Location: InterContinental New York Barclay
- TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit, September 26th 2024:
- Format: Fireside chat
- Presentation Date/Time: Thursday, September 26, 2024, at 3:00 pm ET
- Location: Virtual
Available presentations will be accessible via live webcast on the Events and Presentations page in the Investors section of Alto’s website and a replay will be available following the presentation.
About Alto Neuroscience
Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia, and other mental health conditions.
For more information, visit www.altoneuroscience.com or follow Alto on X (Twitter).
Forward-Looking Statements
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “expects,” “plans,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding Alto’s expectations for the timing and results of Alto’s Phase 2b study of ALTO-100. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including uncertainties inherent in the initiation, progress and completion of clinical trials and other important factors, any of which could cause Alto’s actual results to differ from those contained in the forward-looking statements, which are described in greater detail in the section titled “Risk Factors” in Alto’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Alto may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alto expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as required by law.
Availability of Information on Alto’s Website
Alto routinely uses its investor relations website (https://investors.altoneuroscience.com) to post presentations to investors and other important information, including information that may be material. Accordingly, Alto encourages investors and others interested in Alto to review the information it makes public on its investor relations website.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903163152/en/
